Trials that use: Difference of means/proportions (unspecified test)
New to this method? Read the tutorial →
5 results
- CARE-MS IIndependent statistical analysis of CARE-MS I, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including endpoint definitions, hazard ratios, rate ratios, longitudinal analyses, and statistical interpretation.
- CARE-MS IIComplete statistical analysis of CARE-MS II, a randomized phase 3 trial comparing alemtuzumab with interferon beta-1a in relapsing-remitting multiple sclerosis, including primary endpoints, statistical methods, secondary analyses, safety, and interpretation.
- iPrExIndependent statistical analysis of the randomized phase 3 iPrEx trial of daily TDF/FTC versus placebo for HIV prevention in men, including primary efficacy and safety endpoints, secondary analyses, statistical methods, and interpretation.
- ISABELA 1Independent statistical analysis of ISABELA 1 (NCT03711162), a randomized phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis, including FVC decline, disease progression, hospitalization, mixed-effects models, logistic regression, Cox models, and safety.
- ISABELA 2Complete statistical analysis of the ISABELA 2 phase 3 trial of GLPG1690 in idiopathic pulmonary fibrosis, including trial design, FVC decline, disease progression, hospitalization, survival endpoints, safety, statistical methodology, and interpretation.